Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Barter, P.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Role of nicotinic acid in raising high-density lipoprotein cholesterol (HDL-C) to reduce cardiovascular risk: an Asian/Pacific consensus

The Pan-Asian Consensus Panel On Hdl-C

Philip Barter

The Heart Research Institute, 145 Missenden Road, Camperdown, Sydney 2050, Australia, pbarter{at}ozemail.com.au

ardiovascular disease is a leading cause of morbidity and mortality in Asia, and the burden of disease is expected to rise further in the 21st century. As in Western populations, dyslipidaemia is an important cardiovascular risk factor in Asian people. International guidelines focus on reduction of low-density lipoprotein cholesterol (LDL-C) for prevention and treatment of coronary heart disease (CHD). However, increasing body mass index and prevalence of type 2 diabetes and metabolic syndrome in Asia have highlighted the importance of low levels of high-density lipoprotein cholesterol (HDL-C) as a coronary risk factor. Therapeutic lifestyle changes and pharmacological intervention aimed at raising HDL-C, should benefit such patients. Weight loss and physical However, to achieve target HDL-C levels exercise are important interventions for raising HDL-C. pharmacological intervention is usually necessary. Current treatment options include statins, fibrates and nicotinic acid, either as monotherapy or in combination. Statins are generally regarded as the foundation of lipid-modifying therapy. Mainly via reduction of LDL-C. Both fibrates and nicotinic acidare effective in raising HDL-C levels, and reducing triglyceride-rich lipoproteins. The efficacy and safety profile of nicotinic acid demonstrated in Western populations indicates the clinical benefits of this therapy either alone or in combination with a statin. Based on the available evidence, the Pan-Asian Consensus Panel recommends that HDL-C levels should be raised to at least 1.0 mmol/L (40 mg/dL) in Asian patients with CHD or with a high level of risk for premature vascular disease, including patients at high risk with type 2 diabetes or the metabolic syndrome.

Key Words: high-density lipoprotein cholesterol • coronary heart disease • Asia • type 2 diabetes • metabolic syndrome.

References

  • Tai ES, Tan CE Genes, diet and serum lipid concentrations: lessons from ethnically diverse populations and their relevance to coronary heart disease in Asia. Curr Opin Lipidol 2004;15:5-12.to coronary heart dis[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • World Health Organization South-East Asia. Health situation in SouthEast Asia Region. http://w3.whosea.org/health_situt_98-00/tab42.htm. Accessed 21 January 2005.
  • Canadian Cardiovascular Society. 1998 Consensus Conference on the prevention of cardiovascular diseases. http://www.ccs.ca/society/conferences/archives/1998/1998coneng-12.asp. Accessed 21 January 2005.
  • Yusuf S., Reddy S., Ounpuu S., Anand S. Global burden of cardiovascular diseases. Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation 2001;104:2855-64.[Abstract/Free Full Text]
  • Enas EA Coronary artery disease epidemic in Indians: a cause for alarm and call for action. J Indian Med Assoc 2000;98:694-5,697-702.
  • Lee J., Heng D., Chia KS, Chew SK, Tan BY, Hughes K. Risk factors and incident coronary heart disease in Chinese, Malay and Asian Indian males: the Singapore Cardiovascular Cohort Study. Int J Epidemiol 2001;30:983-8.[Abstract/Free Full Text]
  • Yusuf S., Hawken S., Ounpuu S. et al. Effect of potentially modifiable risk-factors associated with myocardial infarction in 52 countries (the INTER-HEART study): case-control study. Lancet 2004;364:937-52.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Asia Pacific Cohort Studies Collaboration. Cholesterol. Coronary heart disease, and stroke in the Asia Pacific Region. Int J Epidemiol 2003;32:563-72.[Abstract/Free Full Text]
  • People's Republic of China - United States Cardiovascular and Cardiopulmonary Epidemiology Research Group. An epidemiological study of cardiovascular and cardiopulmonary disease risk factors in four populations in the People's Republic of China. Baseline report from the PRC-USA Collaborative Study. Circulation 1992;85:1083-96.[Free Full Text]
  • Blood pressure, cholesterol and stroke in eastern Asia. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Lancet 1998;352:1801-07.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.[Free Full Text]
  • International Atherosclerosis Society. Harmonized clinical guidelines on prevention of atherosclerotic vascular disease. http://www.athero.org[IntegratingtheguidelinesoftheInternationalTaskForceforPreventionofCoronaryHeartDisease,http://www.chd-taskforce.de/guidelines/toc.htm
  • National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand. Lipid management guidelines. Med J Aust 2001;175 (suppl):S57-S85.[Medline] [Order article via Infotrieve]
  • American Diabetes Association. Dyslipidaemia management in adults with diabetes. Diabetes Care 2004;27(suppl 1):S68-S71.[CrossRef][Medline] [Order article via Infotrieve]
  • Cannon CP, Braunwald E., McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.[Abstract/Free Full Text]
  • Sacks FM, Tonkin AM, Shepherd J. et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. The Prospective Pravastatin Pooling Project. Circulation 2000;102:1893-900.[Abstract/Free Full Text]
  • Ballantyne CM, Olsson AG, Cook TJ, Mercuri M., Pedersen TR, Kjekshus J. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001;104:3046-51.[Abstract/Free Full Text]
  • Gordon T., Castelli WP, Hjortland MC, Kannel WB, Dawber TR High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707-14.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Assmann G., Schulte H., von Eckardstein A., Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996;124(suppl):S11-S20.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Gordon DJ, Probstfield JL, Garrison RJ et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American stud-dies. Circulation 1989;79:8-15.[Abstract/Free Full Text]
  • Pan W.-H., Chiang BN Plasma lipid profiles and epidemiology of athersclerotic diseases in Taiwan - a unique experience. Atherosclerosis 1995;118:285-95.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Nishtar S., Wierzbicki AS, Lumb PJ et al. Waist-hip ratio and low HDL predict the risk of coronary artery disease in Pakistanis. Curr Med Res Opin 2004;20:55-62.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Li JZ, Chen ML, Wang S., Dong J., Zeng P., Hou LW A long-term follow-up study of serum lipid levels and coronary heart disease in the elderly. Chin Med J (Eng) 2004;117:163-7.
  • Tao S., Li Y., Xiao Z. et al. Serum lipids and their correlates in Chinese urban and rural populations of Beijing and Guangzhou. PRC-USA Cardiovascular and Cardiopulmonary Epidemiology Research Group. Int J Epidemiol 1992;21:893-903.[Abstract/Free Full Text]
  • Soyama Y., Miura K., Morikawa Y. et al. High-density lipoprotein cholesterol and risk of stroke in Japanese men and women. The Oyabe Study. Stroke 2003;34:963-8.
  • Lee YD Survey on heart diseases in Chin-San area - five year pilot stuies. Report to Department of Health Executive Yuan, Republic of China, 1993.
  • Schaefer EJ, Lamon-Fava S., Ordovas JM et al. Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study. J Lipid Res 1994;35:871-82.[Abstract]
  • He J., Gu D., Reynolds K. et al. Serum total and lipoprotein cholesterol levels and awareness, treatment, and control of hypercholesterolaemia in China. Circulation 2004;110:405-11.[Abstract/Free Full Text]
  • Thomas GN, Ho SY, Lam KS, Janus ED, Hedley AJ, Lam TH; Hong Kong Cardiovascular Risk Factor Prevalence Study Steering Committee. Impact of obesity and body fat distribution on cardiovascular risk factors in Hong Kong Chinese. Obes Res 2004;12:1805-13.[Web of Science][Medline] [Order article via Infotrieve]
  • Enas EA, Garg A., Davidson MA, Nair VM, Huet BA, Yusuf S. Coronary heart disease and its risk factors in first-generation Asian Indians to the United States of America. Indian Heart J 1996;48:343-53.[Medline] [Order article via Infotrieve]
  • Tjokroprawiro A., Pranoto A., Adi S. et al. The metabolic syndrome and dyslipidaemia specified on low HDLC. Presented at: Expert Panel: The critical importance of suboptimal HDL-C in at risk patients in the Asia Pacific Region. Hong Kong, 26 February, 2005.
  • Kim Y., Suh YK, Choi H. BMI and metabolic disorders in South Korean adults: 1998 Korea National Health and Nutrition Survey. Obes Res 2004;12:445-53.[Web of Science][Medline] [Order article via Infotrieve]
  • Khoo KL, Tan H., Liew YM Serum lipids and their relationship with other risk factors in healthy subjects in a city clinic. Med J Malaysia 1997;52:38-52.[Medline] [Order article via Infotrieve]
  • Sy RG, Dans AL, Punzalan FER et al. The prevalence of dyslipidaemia, diabetes, hypertension, stroke and angina pectoris in the Philippines. Phil J Internal Med 2003;41:1-6.
  • Ministry of Health, Singapore. Epidemiology and Disease Control Department. National Health Survey 1998. Singapore: Ministry of Health; 1999.
  • Chang H.-Y., Yeh W.-T., Chang Y.-H., Tsai K.-S., Pan W.-H. Prevalence of dyslipidemia and mean blood lipid values in Taiwan: results from the Nutrition and Health Survey in Taiwan (NAHSIT, 1993-1996). Chin J Physiol 2002;45:187-97.[Web of Science][Medline] [Order article via Infotrieve]
  • Yipintsoi T., Lim A., Jintapakorn W. Prevalence of cardiovascular risk factors in a rural area of southern Thailand: potential ethnic differences. J Med Assoc Thai 2005;88:196-204.[Medline] [Order article via Infotrieve]
  • Simons LA Interrelations of lipids and lipoproteins with coronary artery disease mortality in 19 countries. Am J Cardiol 1986:57:5G-10G.[CrossRef][Medline] [Order article via Infotrieve]
  • Kuzuya M., Ando F., Iguchi A., Shimokata H. Changes in serum lipid levels during a 10 year period in a large Japanese population. A cross-sectional and longitudinal study. Atherosclerosis 2002;163:313-20.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 0. Zhao L-C., Li Y., Wu Y-F et al. Relation of body mass index and waist circumference to the level of high density lipoprotein cholesterol (HDL-C) and low HDL-C prevalence. Chin J Cardiol 2003;31:302 [abstract) [Chinese].
  • Li Z., Yang R., Xu G., Xia T. Serum lipid concentrations and prevalence of dyslipidemia in a large professional population in Beijing. Clin Chem 2005;51:144-50.[Abstract/Free Full Text]
  • Kuzawa CW, Adair LS, Avila JL et al. Atherogenic lipid profiles in Filipino adolescents with low body mass and low dietary fat intake. Am J Hum Biol 2003;15:688-96.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Basit A., Hydrie MZI, Hakeem R. et al. Frequency of chronic complications of type II diabetes. J Coll Phys Surg Pakistan 2004;14:79-83.
  • Tjokroprawiro A., Adi S., Wibisono S., Umi M. Dyslipidemia: specified on low HDL-C, and high Lp(a) (as observed on 500 patients with T2DM in Surabaya). International Merck Symposium on importance of HDL-C. Rome, 1-2 October, 2004.
  • Park KW, Choi JH, Kim HK et al. The association of cholesteryl ester transfer protein polymorphisms with high-density lipoprotein cholesterol and coronary artery disease in Koreans. Clin Genet 2003;63:31-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Ikewaki K., Mabuchi H., Teramoto T. et al. Association of cholesteryl ester transfer protein activity and TaqIB polymorphism with lipoprotein variations in Japanese subjects. Metabolism 2003;52:1564-70.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Motohashi Y., Maruyama T., Murata M. et al. Role of genetic factors (CETP gene Taq IB polymorphism and Apo A-I gene Msp I polymorphism) in serum HDL-C levels in women. Nutr Metab Cardiovasc 2004;14:6-14.[CrossRef]
  • Downs JR, Clearfield M., Weis S. et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22.[Abstract/Free Full Text]
  • Manninen V., Elo MO, Frick MH et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988;260:641-51.[Abstract/Free Full Text]
  • Rubins HB, Robins SJ, Collins D. et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-18.[Abstract/Free Full Text]
  • Brown G., Albers JJ, Fisher LD et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98.[Abstract]
  • Robins SJ, Collins D., Wittes JT et al. Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: a randomized controlled trial. JAMA 2002;285:1585-91.[Web of Science]
  • Alsheikh-Ali AA, Kuvin JT, Karas RH High-density lipoprotein cholesterol in the cardiovascular equation: does the `good` still count? Atherosclerosis 2005;180:217-23.[Medline] [Order article via Infotrieve]
  • Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-81.[Abstract/Free Full Text]
  • Canner PL, Berge KG, Wenger NK et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55.[Abstract]
  • Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988;223:405-18.[Web of Science][Medline] [Order article via Infotrieve]
  • Sacks FM and the Expert Group on HDL Cholesterol. The role of high density lipoprotein cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 2002;90:139-42.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Assmann G., Nofer J.-R. Atheroprotective effects of high-density lipoproteins. Ann Rev Med 2003;54:321-41.[CrossRef][Medline] [Order article via Infotrieve]
  • Chapman MJ, Assman G., Fruchart JC, Shepherd J., Sirtori C., on behalf of the European Consensus Panel on HDL-C. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid - a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 2004;20:1253-68.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Barter PJ, Rye K.-A. High density lipoproteins and coronary heart disease. Atherosclerosis 1996;121:1-12.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Le Goff W., Guerin M., Chapman MJ Pharmacological modulation of cholesteryl ester transfer protein: a new therapeutic target in atherogenic dyslipidemia. Pharmacol Ther 2004;101:17-38.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Chiesa G., Monteggia E., Marchesi M. et al. Recombinant apolipoprotein A-I (Milano) infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. Circ Res 2002;90:974-80.[Abstract/Free Full Text]
  • Nissen SE, Tsunoda T., Tuzeu EM et al. Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes. A randomized controlled trial. JAMA 2003;290:2292-300.[Abstract/Free Full Text]
  • Calabresi L., Gomaraschi M., Franceschini G. Endothelial protection by high-density lipoproteins. Arterioscler Thromb Vasc Biol 2003;23:1724-31.[Abstract/Free Full Text]
  • Nofer J.-R, Levkau B., Wolinska I. et al. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysospingolipids. J Biol Chem 2001;276:34480-5.[Abstract/Free Full Text]
  • Spieker LE, Sudano I., Hurlimann D. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 2002;105:1399-402.[Abstract/Free Full Text]
  • Cockerill GW, Huehns TY, Weerasinghe A. et al. Elevation of plasma high density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation 2001;103:108-12.[Abstract/Free Full Text]
  • Navab M., Berliner JA, Subbanagounder G. et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 2001;21:481-8.[Abstract/Free Full Text]
  • Moon OR, Kim NS, Jang SM, Yoon TH, Kim SO The relationship between body mass index and the prevalence of obesity-related diseases based on the 1995 National Health Interview Survey in Korea. Obes Res 2002;3:191-6.
  • Lin WY, Lee LT, Chen CY et al. Optimal cut-off values for obesity: using simple anthropometric indices to predict cardiovascular risk factors in Taiwan. Int J Obes Relat Metab Disord 2002;26:1232-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • The Steering Committee of the regional office for the Western Pacific Region of the WHO, the International Association for the Study of Obesity and the International Obesity Task Force. The Asia-Pacific Perspective: redefining obesity and its treatment. Health Communications Australia Pty Limited (2000). Available from http://www.idi.org.au/download/obesity_report.pdf
  • Zimmet P., Alberti Kgmm, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414:782-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • World Health Organization, World Health Report, 1997.
  • Diabetes Atlas, International Diabetes Federation, 2000.
  • White F., Rafique G. Diabetes prevalence and projections in South Asia. Lancet 2002;360:804-5 [letter].[Medline] [Order article via Infotrieve]
  • Gu D., Reynolds K., Duan X. et al. Prevalence of diabetes and impaired fasting glucose in the Chinese adult population: International Collaborative Study of Cardiovascular Disease in Asia (InterASIA). Diabetologia 2003;46:1190-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Aekplakorn W., Stolk RP, Neal B. et al. The prevalence and management of diabetes in Thai adults. Diabetes Care 2003;26:2758-63.[Abstract/Free Full Text]
  • Zaini A. Where is Malaysia in the midst of the Asian epidemic of diabetes mellitus? Diabetes Res Clin Pract 2000;50(suppl 2):S23-S28.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Lee WR, Lee CH Current aspects of diabetes mellitus and lifestyle disease in Singapore. J Asian Fed Endocr Soc 1999;17:14-17.
  • Chuang SY, Chen CH, Tsai ST, Chow P. Clinical identification of the metabolic syndrome in kinmen. Acta Cardiol Sin 2002;18:16-23.
  • Day C. The rising tide of type diabetes. Br J Diabetes Vasc Dis 2001;1:37-43.[Abstract/Free Full Text]
  • Lee ZS, Critchley JA, Chan JC et al. Obesity is the key determinant of cardiovascular risk factors in the Hong Kong Chinese population: cross-sectional clinic-based study. HK Med J 2000;6:13-23.
  • Hydrie MZI, Basit A., Badruddin N. et al. Diabetes risk factors in middle income Pakistani school children. Pakistan J Nutr 2004;3:43-9.
  • Hydrie MZI, Basit A., Ahmedani MY et al. Comparison of risk factors for-diabetes in children of different socio-economic status. JCPSP 2005;15:74-7.[Medline] [Order article via Infotrieve]
  • Barnett AH Dyslipidaemia in ethnic populations: special considerations. Br J Cardiol 2005;12:118-22.
  • Whincup PH, Gilg JA, Papacosta O. et al. Early evidence of ethnic differences in cardiovascular risk: cross sectional comparison of British South Asian and white children. Br Med J 2002;324:1-6.[Free Full Text]
  • Kannel WB Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J 1985;110:1100-07.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Stamler J., Vaccaro O., Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44.[Abstract]
  • Haffner SM, Lehto S., Ronnemaa T., Pyorala K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.[Abstract/Free Full Text]
  • Moon YSK, Kashyap ML Pharmacologic treatment of type 2 diabetic dyslipidemia. Pharmacother 2004;24:1692-713.[CrossRef]
  • Taskinen MR Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003;46:733-49.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Drexel H., Aczel S., Marte T. et al. Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol? Diabetes Care 2005;28:101-07.[Abstract/Free Full Text]
  • Anand S., Enas E., Pogue J. et al. Elevated lipoprotein(a) levels in South Asians in North America. Metabolism 1998;47:182-4.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Luc G., Bard J-M., Arveiler D. et al. Lipoprotein (a) as a predictor of coronary heart disease: the PRIME study. Atherosclerosis as 2002;163:377-84.
  • Bhopal R., Unwin N., White M. et al. Heterogeneity of coronary heart disease risk factors in Indian, Pakistani, Bangladeshi, and European origin populations: cross sectional study. Br Med J 1999;319:215-20.[Abstract/Free Full Text]
  • The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.[Abstract/Free Full Text]
  • Pyorala K., Pedersen TR, Kjekshus J., Faedeman O., Olsson A., Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patents with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614-20.[Abstract]
  • Goldberg RB, Mellies MJ, Sacks FM et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the Cholesterol and Recurrent Events (CARE) Trial. Circulation 1998;98:2513-19.[Abstract/Free Full Text]
  • Chapman MJ Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 2003;171:1-13.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Superko HR, Krauss RM Differential effects of nicotinic acid in subjects with different LDL subclass patterns. Atherosclerosis 1992;95:69-76.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med 2004;164:697-705.[Abstract/Free Full Text]
  • Brown BG, Zhao XQ, Chait A. et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92.[Abstract/Free Full Text]
  • Canner PL, Furberg CD, Terrin ML, McGovern ME Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2005;95:254-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Alberti KG, Zimmet PZ Definition, diagnosis, and classification of diabetes mellitus and its complications. Part I. Diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation Diabet Med 1998;15:539-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • The IDF consensus worldwide definition of the metabolic syndrome. April 14, 2005. Available from: http://www.idf.org
  • Misra A., Wasir JS, Pandey RM An evaluation of candidate definitions of the metabolic syndrome in adult Asian Indians. Diabetes Care 2005;28:398-403.[Abstract/Free Full Text]
  • Thomas GN, Ho S-Y., Janus ED et al. The US National Education Programme Adult Treatment Panel III (NCEP ATPIII) prevalence of the metabolic syndrome in a Chinese population. Diabet Res Clin Pract 2005;67:251-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Shiwaku K., Nogi A., Kitajima K. et al. Prevalence of the metabolic syndrome using the modified ATPIII definitions for workers in Japan, Korea and Mongolia. J Occup Health 2005;47:126-35.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Lee WY, Park JS, Noh SY, Rhee EJ, Kim SW, Zimmet PZ Prevalence of the metabolic syndrome among 40,698 Korean metropolitan subjects. Diabetes Res Clin Pract 2004;65:143-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Oh J-Y., Hong YS, Sung Y.-A. Barrett-Connor E. Prevalence and factor analysis of metabolic syndrome in an urban Korean population. Diabetes Care 2004;27:2027-32.[Abstract/Free Full Text]
  • Punzalan FER, Sy RG, Ty-Willing T. Prevalence of metabolic syndrome among adult Filipinos. Int Congress Series 2004;1262:442-5.[CrossRef]
  • Tan C-E., Ma S., Wai D., Chew S-K., Tai E-S. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care 2004;27:1182-6.[Abstract/Free Full Text]
  • Chuang S.-Y, Chen C.-H, Chou P. Prevalence of metabolic syndrome in a large health check-up population in Taiwan. J Chin Med Assoc 2004;67:611-20.[Medline] [Order article via Infotrieve]
  • Zhao X-Q., Morse J., Chait A. et al. Simvastatin plus niacin protect against atherosclerosis progression and clinical events in coronary artery disease patients with metabolic syndrome. J Am Coll Cardiol 2002;39(suppl A): 242A (abstract 1130-73).
  • Canner PL, Furberg CD, Terrin ML, McGovern ME Niacin decreases myocardial infarction and total mortality in patients with metabolic syndrome: results from the Coronary Drug Project. J Am Coll Cardiol 2003;41(suppl A):291A [abstract].
  • Schaefer EJ, Lamon-Fava S., Cohn SD et al. Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study. J Lipid Res 1994;35:779-92.[Abstract]
  • Stevenson JC, Crook D., Godsland IF Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 1993;98:83-90.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Davidson MH, Maki KC, Karp SK, Ingram KA Management of hyper-cholesterolaemia in postmenopausal women. Drugs Aging 2002;19:169-78.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Torng PL, Su TC, Sung FC et al. Effects of menopause on individual changes in serum lipids, blood pressure, and body weight - the ChinShan Community Cardiovascular Cohort study. Atherosclerosis 2002;161:409-15.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Yamamoto A., Horibe H., Mabuchi H. et al. Analysis of serum lipid levels in Japanese men and women according to body mass index. Increase in risk of atherosclerosis in postmenopausal women. Research Group on Serum Lipid Survey 1990 in Japan. Atherosclerosis 1999;143:55-73. clinical trial data. Cardiol Rev 2003;11:4-12.[CrossRef][Medline] [Order article via Infotrieve]
  • Mostaghel E., Waters D. Women do benefit from lipid lowering: latest clinical trial data. Cardio Rev 2003;11:4-12.[CrossRef]
  • Herrington DM, Vittinghoff E., Lin F. et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation 2002;105:2962-7.[Abstract/Free Full Text]
  • Sacks FM, Pfeffer MA, Moyle LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-09.[Abstract/Free Full Text]
  • Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Robins SJ, Rubins HB, Faas HF et al. Insulin resistance and cardiovascular events with low HDL cholesterol. The Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care 2003;26:1513-17.[Abstract/Free Full Text]
  • Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Goldberg RB, Mellies MJ, Sacks FM et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) Trial. Circulation 1998; 98:2513-19.[Abstract/Free Full Text]
  • Pyörälä K., Ballantyne CM, Gumbiner B. et al. Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 2004;27: 1735-40.[Abstract/Free Full Text]
  • The UK HDL-C Consensus Group. Role of fibrates in reducing coronary risk: a UK consensus. Curr Med Res Opin 2004;20:241-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Rubins HB, Robins SJ, Collins D. et al. Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group. Am J Cardiol 1995;75:1196-201.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Guérin M., Le Goff W., Lassel TS, Van Tol A., Steiner G., Chapman MJ Proatherogenic role of elevated CE transfer from HDL to VLDL1 and dense LDL in type 2 diabetes. Impact of the degree of triglyceridemia. Arterioscler Thromb Vasc Biol 2001;21:282-8.[Abstract/Free Full Text]
  • Van Gaal LF, Wauters MA, De Leeuw IH The beneficial effects of modest weight loss on cardiovascular risk factors. Int J Obes Relat Metab Disord 1997;21(suppl 1):S5-S9.[Web of Science]
  • Belalcazar LM, Ballantyne CM Defining specific goals of therapy in treating dyslipidemia in the patient with low high-density lipoprotein cholesterol. Progr Cardiovasc Dis 1998;41:151-74.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;357:905-10.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Grundy SM, Vega GL, Yuan Z. et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (The SAFARI Trial). Am J Cardiol 2005;95:462-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Wierzbicki AS, Mikhailidis DP, Wray R. et al. Statin-fibrate combination therapy for hyperlipidaemia: a review. Curr Med Res Opin 2003;19:15568.
  • Goldberg A., Alagona P. Jr, Capuzzi DM et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol 2000;85:1100-05.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Sprecher D. Raising high-density lipoprotein cholesterol with niacin and fibrates: a comparative review Am J Cardiol 2000;86(suppl):46L-50L.[Web of Science][Medline] [Order article via Infotrieve]
  • Knopp RH, Alagona P., Davidson M. et al. Equivalent efficacy of a timerelease form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolis 1998;47:1097-104.
  • Morgan JM, Capuzzi DM, Guyton JR et al. Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled trial. J Cardiovasc Pharmacol Ther 1996;1:195-202.[Medline] [Order article via Infotrieve]
  • Kashyap ML, McGovern ME, Berra K. et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 2002;89:672-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Capuzzi DM, Morgan JM, Weiss RJ, Chitra RR, Hutchinson HG, Cressman MD Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels. Am J Cardiol 2003;91:1304-10.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Grundy SM, Vega GL, McGovern ME et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Results of the Assessment of Diabetes control and Evaluation of the Efficacy of Niaspan Trial. Arch Intern Med 2002;162:1568-76.[Abstract/Free Full Text]
  • Ganji SH, Kamanna VS, Kashyap ML Niacin and cholesterol: role in cardiovascular disease (review). J Nutr Biochem 2003;14:298-305.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Davidson MH Combination therapy for dyslipidaemia: safety and regulatory considerations. Am J Cardiol 2002;90(suppl):50K-60K.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Guyton JR, Goldberg AC, Kreisberg RA, Sprecher DL, Superko HR, O'Connor CM Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol 1998;82:737-43.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Wolfe ML, Vartanian SF, Ross JL et al. Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. Am J Cardiol 2001;87:476-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Taylor AJ, Sullenberger LE, Lee HJ et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2. Circulation 2004;110:3512-17.[Abstract/Free Full Text]
  • Blankenhorn DH, Selzer RH, Crawford DW et al. Effects of colestipolniacin therapy on the common carotid artery: two- and four-year reduction of intima-media thickness measured by ultrasound. Circulation 1993;88:20-8.[Abstract/Free Full Text]
  • Greenland P., Abrams J., Aurigemma GP et al. AHA Scientific Statement. Prevention Conference V. Beyond secondary prevention: identifying the high-risk patient for primary prevention: non-invasive tests of atherosclerotic burden: Writing Group III. Circulation 2000;101:e16-22.[Medline] [Order article via Infotrieve]
  • Whitney EJ, Krasuski RA, Personius BE et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effect on progression of coronary heart disease and clinical events. Ann Intern Med 2005;142:95-104.[Abstract/Free Full Text]
  • Garg A., Grundy SM Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA 1990;264:723-6.[Abstract/Free Full Text]
  • McGovern ME Use of nicotinic acid in patients with elevated fasting glucose, diabetes, or metabolic syndrome. Br J Diabetes Vasc Dis 2004;4:78-85.[Abstract/Free Full Text]
  • Elam MB, Hunninghake DB, Davis KB et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. The ADMIT study: a randomized trial. JAMA 2000;284:1263-70.[Abstract/Free Full Text]
  • Birjmohun RS, Hutten BA, Kastelein JJP, Stroes ESG. Efficacy and safety-of high-density lipoprotein cholesterol-increasing compounds. A meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005;45:185-97.[Abstract/Free Full Text]
  • 57. Zhao X-Q., Morse JS, Dowdy AA et al. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (the HDL Atherosclerosis Treatment Study). Am J Cardiol 2004;93:307-12.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Guyton JR Extended-release niacin for modifying the lipoprotein profile. Expert Opin Pharmacother 2004;5:1-14.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Mosca L., Appel LJ, Benjamin EJ et al. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 2004;109:672-93.[Free Full Text]

The British Journal of Diabetes & Vascular Disease, Vol. 5, No. 2 suppl, S1-S15 (2005)
DOI: 10.1177/14746514050050020101
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Barter, P.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?